Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders

Brankovic M, Gmizic T, Dukic M, Zdravkovic M, Daskalovic B, Mrda D, Nikolic N, Brajkovic M, Gojgic M, Lalatovic J, Kralj D, Pantic I, Vojnovic M, Milovanovic T, Durasevic S, Todorovic Z. Antioxidants (Basel). 2024;13(5):600.

ReviewHumans

Design

Review

Subjects

Narrative review

Dose used in the study

Not applicable

Duration

Not applicable

What was measured

Effects on gut motility, microbiota and inflammation, and studies in irritable bowel syndrome and inflammatory bowel disease

What the authors reported

Benefit reported in irritable bowel and inflammatory bowel disease studies, with a lack of toxicity at high doses; the authors call for more human studies.

Limits of this study

Narrative, not systematic. The abstract's statement that dietary intake cannot reach a therapeutic level is an inference, not a measured finding. One author works for a pharmaceutical company. Open access, MDPI.

Source

PubMed 38790705 · doi:10.3390/antiox13050600

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.